AstraZeneca has announced a $1.5-billion cost-savings plan over three years designed to support capital flow in the company’s existing business and therapy areas. The company highlighted the plan as part of its third-quarter 2026 earnings announcement on October 30, 2026. 

The plan, dubbed the Reshaping for Sustainable Growth (RSG) program, is expected to cost up to $2.0 billion in one-time restructuring costs and deliver $1.5 billion in annualized pre-tax run-rate benefits. The company says that the savings generated will continue to be reinvested back into the company, principally in its pipeline. While not offering specific details on where the cost-savings will be directed, the company says it anticipates activities from the RSG program will be essentially complete by the end of 2029. 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said in the company’s earnings release, that the company remains on track to reach its previously stated goal of reaching overall annual revenues of $80 billion by 2030. For the full-year 2025, the company reported annual revenues of $58.7 billion, and in the first nine months of 2026, $46.9 billion, up 7% year over year.  

Three therapeutic segments—oncology, respiratory & immunology, and rare diseases— reported double-digit growth through the first nine months of 2026. Revenues for oncology medicines, which accounted for 47% of the company’s revenues for the first nine-months of 2026, increased 16% (at constant exchange rates [CER]) year over year and reached $21.9 billion. Medicines for rare diseases, which accounted for 16% of revenues for the first nine months of 2026, increased 11% (at CER) to reach $7.5 billion. The company’s BioPharmaceuticals Segment, which includes three main therapeutic areas—cardiovascular, renal & metabolism, respiratory & immunology, and infectious diseases—posted overall revenues of $16.7 billion for the first nine months of 2026, representing 36% of overall revenues, but an overall revenue decline of 5% year over year. Respiratory & immunology was the only area showing growth (+10%) while the cardiovascular, renal & metabolism area posted a 14% decline and the infectious disease area, a 12% decline. The cardiovascular, renal & metabolism area had revenue declines for Farxiga (dapagliflozin), a drug for treating Type II diabetes, in which the first generic was approved earlier this year (April 2026) and revenue declines for Brilinta (ticagrelor), an antiplatelet medication, which continued to see generics incursion.  

In highlighting the growth trajectory from its pipeline, the company says it has more than 180 projects in its pipeline, of which 116 are new molecular entities (NMEs) or are for major life-cycle management in either Phase II or Phase III development, which includes 20 NMEs in late-stage development and two NMEs under regulatory review.  

Source: AstraZeneca